Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881088 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1 | |
| SCHEMBL17075454 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1 | |
| SCHEMBL8069784 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL8037347 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL12631559 | 0.83 | ADORA2A (0.70) | ADORA2AADORA1 | |
| SCHEMBL1864144 | 0.82 | ADORA2A (0.68) | ADORA2AADORA1 | |
| SCHEMBL17085185 | 0.81 | ADORA2A (0.69) | ADORA2AADORA1 | |
| SCHEMBL12070698 | 0.81 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL8073095 | 0.80 | ADORA2A (0.69) | ADORA2AADORA1 | |
| SCHEMBL8072372 | 0.80 | ADORA2A (0.73) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4725963-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| EP-1673354-B1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-04-22 | — | — | EP | claimed |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-26 | — | — | US | claimed |
| JP-2007521243-A | — | — | 2007-08-02 | — | — | JP | claimed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | claimed |
| EP-1673354-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-06-28 | — | — | EP | claimed |
| US-20050267138-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | HEINTZELMAN GEOFFREY R | 2005-12-01 | — | — | US | claimed |
| WO-2005042500-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONIST | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-20040127510-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL, INC. | 2004-07-01 | — | — | US | claimed |
| US-20110312956-A1 | ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312956-A1 | ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | US | disclosed |
| WO-2011159302-A1 | ARYLINDENOPYRIMIDINES FOR TREATING NEURODEGENERATIVE AND MOVEMENT DISORDERS WHILE MINIMIZING CARDIAC TOXICITY | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| US-7759356-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759356-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-20 | — | — | US | disclosed |
| US-20050267142-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | HEINTZELMAN GEOFFREY R | 2005-12-01 | — | — | US | disclosed |
| US-20050239810-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | HEINTZELMAN GEOFFREY R | 2005-10-27 | — | — | US | disclosed |
| US-20050239812-A1 | Adenosine A2a receptors antagonist; 9H-indeno[2,1-c]pyridine-4-carboxylic acid, 3-amino-1-furan-2-yl-9-oxo-, 2-dimethylamino-ethyl ester; neurodegenerative and movement disease, as Parkinson's; improves binding affinity of Dopamine D2 agonist to their receptors | HEINTZELMAN GEOFFREY R | 2005-10-27 | — | — | US | disclosed |
| WO-2005042500-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONIST | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042500-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONIST | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040127510-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239810-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
| US-20040127510-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
| US-20050267138-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
| US-20050239812-A1 | Adenosine A2a receptors antagonist; 9H-indeno[2,1-c]pyridine-4-carboxylic acid, 3-amino-1-furan-2-yl-9-oxo-, 2-dimethylamino-ethyl ester; neurodegenerative and movement disease, as Parkinson's; improves binding affinity of Dopamine D2 agonist to their receptors | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885 |
| US-20110312956-A1 | ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING | ADORA2A, ADORA1, P2RX5 | ADORA2A 1/4885ADORA1 2/4885 |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
| US-20050267142-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.